Navigation Links
Reynolds American Subsidiary to Receive Payment Following Gallaher Joint-Venture Termination
Date:2/21/2008

WINSTON-SALEM, N.C., Feb. 21 /PRNewswire-FirstCall/ -- Reynolds American Inc. (NYSE: RAI) announced today that R.J. Reynolds Tobacco C.V. (RJRTCV), an indirect wholly owned subsidiary of RAI, will receive a payment of euro 265.0 million (approximately $387.6 million) from Gallaher Limited (Gallaher), a JT International (JTI) Group company, resulting from the termination of the joint-venture agreement between RJRTCV and a Gallaher affiliate.

In accordance with the terms of the joint venture, RJRTCV will receive 40 percent of that total, euro 106.0 million (approximately $155.0 million), on or before April 20, 2008. Gallaher will pay the remaining 60 percent of the valuation amount in six equal annual installments of euro 26.5 million (approximately $38.8 million), beginning in April 2009. The dollar values reflect a euros-to-dollars exchange rate of 1.4625, calculated on the morning of Feb. 20, 2008.

After accounting for the company's cost basis and discounting the stream of future payments, RAI expects the payment to result in a pre-tax gain of approximately $300 million, which will be recorded in the first quarter of 2008.

The valuation payment results from last year's termination of R.J. Reynolds-Gallaher International Sarl, a Swiss joint venture that was formed by RJRTCV and a Gallaher affiliate in 2002. The joint venture marketed American- blend cigarettes primarily in Italy, France and Spain.

On April 18, 2007, an affiliate of Japan Tobacco Inc. acquired Gallaher Group Plc, which constituted a change of control of Gallaher as defined by the joint-venture agreement. In accordance with the terms of the agreement, RJRTCV elected to terminate the joint venture prior to its expiration date. The joint venture was
'/>"/>

SOURCE Reynolds American Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Congressman Tom Reynolds Awarded for Protecting Medicare Choices
2. Many Older Americans Have Active Sex Lives
3. Despite grumbling, most Americans say they are happy at work
4. Record Number of Americans Lack Health Insurance
5. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
6. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
7. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
8. Novo Nordisk Appoints New Leader of North American Business
9. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
10. Primary biliary cirrhosis more severe in African-American and Hispanic patients
11. AOA President Calls on Congress to Reauthorize SCHIP and Take Action to Ensure Health Care Coverage for All Americans
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2Fresh Blood Boosts Survival in Trauma Patients 58799 1Fresh Blood Boosts Survival in Trauma Patients 58799 2Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 1Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 2Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 3Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 4Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 5Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 1Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 2Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 3Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 4Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 5